NGS molecular diagnostics market seen growing to $3.23 billion by 2030

The next-generation sequencing-based molecular diagnostics market is projected to expand from $2.43 billion in 2026 to $3.23 billion by 2030, according to a new report from The Business Research Company. Growth is tied to infectious disease testing, AI-enabled diagnostics, cloud genomics and broader adoption across clinical labs, with North America leading and Asia-Pacific expected to grow fastest.

Why it matters: - Next-generation sequencing-based molecular diagnostics is becoming a core tool for identifying genetic variations, mutations and disease markers faster and with more detail than traditional testing. - The market’s projected growth signals rising demand for precision medicine, faster pathogen detection and more advanced clinical laboratory workflows. - Infectious disease pressure is also pushing adoption, as sequencing can identify multiple pathogens in a single test.

What happened: - The Business Research Company released its 2026 report on the next-generation sequencing-based molecular diagnostics market on August 19, 2026. - The market is projected to rise from $2.26 billion in 2025 to $2.43 billion in 2026. - The report forecasts the market will reach $3.23 billion by 2030, implying a 7.3% CAGR. - North America held the largest market share in 2025. - Asia-Pacific is expected to post the fastest growth over the forecast period. - The report covers South East Asia, Western Europe, Eastern Europe, South America, the Middle East and Africa. - Download a free sample of the report. - View the full market report.

The details: - The market grew on the back of increased genetic disorder testing, high-throughput sequencing advances, wider clinical laboratory adoption and improvements in sequencing reagents. - The report points to AI and machine learning, cloud-based genomic platforms, portable point-of-care sequencing devices, personalized medicine and tighter collaboration between diagnostics and biotechnology companies as major growth drivers. - Expected product and workflow innovations include AI-powered molecular diagnostics, cloud genomic analysis, portable sequencing tools, integrated bioinformatics pipelines and rapid disease-marker detection. - NGS-based molecular diagnostics uses high-throughput sequencing to analyze genetic material with high accuracy and speed. - The technology helps identify mutations and molecular disease markers and supports data-driven clinical decisions. - Rising healthcare spending, expanding molecular diagnostic capabilities, more genetic disorders and infectious diseases, and supportive government initiatives are driving growth in Asia-Pacific. - The 2026 report adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspot infographics and updated graphics and tables.

Between the lines: - The report frames the market as moving from broad laboratory adoption toward more distributed and software-heavy diagnostics, especially as AI and cloud tools enter genomic analysis. - Infectious disease trends matter because they create a practical use case for sequencing beyond research and into routine clinical testing. - The regional split suggests mature demand in North America and a faster scaling opportunity in Asia-Pacific, where healthcare investment is still expanding. - In February 2024, the UK Health Security Agency reported a 10.7% rise in tuberculosis cases in England, with 4,850 infections in 2023 versus 4,380 in 2022.

What's next: - The market is expected to keep expanding through 2030 as clinical adoption broadens and diagnostic workflows add more AI and cloud-based tools. - Portable and point-of-care sequencing systems could make NGS-based diagnostics more accessible outside large reference labs. - Continued collaboration between diagnostics and biotech companies may accelerate product development and commercialization.

The bottom line: - NGS-based molecular diagnostics is shifting from a high-growth niche into a broader precision-medicine platform, with infectious disease testing and AI-driven workflows likely to define the next phase of expansion.